Abstract: The present invention relates to a sinuous microstructure mixing unit, and also relates to a microfluidic device having the unit, and the use of the unit or the device for preparing nanoparticles, such as lipid nanoparticles or self-assembled particles.

Abstract: The present disclosure relates to codon-optimized sequences coding for hGCDH polypeptide and recombinant adeno-associated virus (rAAV) vectors comprising one of said sequences under the control of a promoter component. Also provided herein are viral particles comprising the rAAV vector, a pharmaceutical composition comprising the rAAV vector or the viral particles, and uses thereof in treating Glutaric aciduria type I (GA-I).

Abstract: Provided is a recombinant adeno-associated viral (rAAV) vector comprising one or two of (a) to (c): (a) a nucleotide sequence encoding aromatic L-amino acid decarboxylase (AADC), (b) a nucleotide sequence encoding glucocerebrosidase (GBA1); and (c) a nucleotide sequence encoding a neurotrophic factor (NTF), such as cerebral dopamine neurotrophic factor (CDNF) or glial cell derived neurotrophic factor (GDNF), for treating neurodegenerative disorders, particularly Parkinson's disease (PD), Multiple system atrophy (MSA), Gaucher's disease (GD), and other proteinopathies. Also provided herein are viral particles comprising the rAAV vector, a pharmaceutical composition comprising the viral particles, and uses thereof.

Abstract: The present disclosure relates to an AAV capsid having improved liver tissue tropism and stronger exogenous gene expression, and/or improved ability in escaping from neutralizing antibody. The present disclosure further relates to a nucleic acid encoding the AAV capsid, an AAV particle containing the AAV capsid. The present disclosure further relates to a pharmaceutical formulation, which contains (1) the AAV capsid, the nucleic acid, or the AAV particle, and (2) a pharmaceutically acceptable carrier. The present disclosure further relates to the use of the AAV capsid, the nucleic acid, the AAV particle, or the pharmaceutical formulation in the manufacture of a drug for delivering a target gene to mammalian cells. The present disclosure further relates to a method for treating disease, including administration of the pharmaceutical formulation to a subject in need thereof. The present disclosure further relates to a cell containing the nucleic acid.

Abstract: The present disclosure provides a recombinant adeno-associated vector comprising a codon-optimized sequence encoding CYP4V2 linked to selected gene expression regulatory sequences and its use in treating Bietti Crystalline Dystrophy (BCD).

Abstract: The present disclosure relates to a method and a device for alarm triggering. The method includes: receiving a trigger instruction on a verification interface; determining whether the received trigger instruction is a predetermined alarm triggering instruction, the predetermined alarm triggering instruction corresponding to at least one contact person; entering an alarm triggering mode if the received trigger instruction is determined to be the predetermined alarm triggering instruction; and sending alarm information to a terminal of the at least one contact, the alarm information indicating that a user is in danger.

Abstract: The present disclosure relates to a method and a device for alarm triggering. The method includes: receiving a trigger instruction on a verification interface; determining whether the received trigger instruction is a predetermined alarm triggering instruction, the predetermined alarm triggering instruction corresponding to at least one contact person; entering an alarm triggering mode if the received trigger instruction is determined to be the predetermined alarm triggering instruction; and sending alarm information to a terminal of the at least one contact, the alarm information indicating that a user is in danger.

Abstract: The present invention provides resveratrol-based boron-containing analog! methods of use thereof in treatment of dyslipidemias and cancer.

Abstract: A compressible and highly flexible plugging agent comprises the following components in parts by weight: 70-80 parts of natural rubber, 0.5-1 part of polyacrylamide (PAM), 1.5-3 parts of polyanionic cellulose (PAC), 0.5-1 part of biopolymer XC and 10-15 parts of ultrafine calcium carbonate; and the preparation method thereof comprises the following steps: adding the components in the weight parts into the natural rubber in order according to the common preparing method at normal temperature and pressure, mixing and stirring evenly, drying and then grinding into particles of 0.05-50 mm. The plugging agent is characterized by wide raw material sources, simple process, safe application, high plugging ratio and high compressibility, which is suitable for oil recovering and geological drilling applications.

Abstract: A compressible and highly flexible plugging agent comprises the following components in parts by weight: 70-80 parts of natural rubber, 0.5-1 part of polyacrylamide (PAM), 1.5-3 parts of polyanionic cellulose (PAC), 0.5-1 part of biopolymer XC and 10-15 parts of ultrafine calcium carbonate; and the preparation method thereof comprises the following steps: adding the components in the weight parts into the natural rubber in order according to the common preparing method at normal temperature and pressure, mixing and stirring evenly, drying and then grinding into particles of 0.05-50 mm. The plugging agent is characterized by wide raw material sources, simple process, safe application, high plugging ratio and high compressibility, which is suitable for oil recovering and geological drilling applications.